OncoMatch/Clinical Trials/NCT05405387

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Is NCT05405387 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Budesonide EC for multiple myeloma.

Phase 2RecruitingUniversity of UtahNCT05405387Data as of May 2026

Treatment: Budesonide EC — A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Prior therapy

Cannot have received: allogeneic stem cell transplant

Lab requirements

Liver function

total bilirubin ≤ 2 x institutional upper limit of normal (uln). ast(sgot)/alt(sgpt) ≤ 5 × institutional uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Huntsman Cancer Institute at the University of Utah · Salt Lake City, Utah

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify